CL2016001210A1 - Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis. - Google Patents

Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.

Info

Publication number
CL2016001210A1
CL2016001210A1 CL2016001210A CL2016001210A CL2016001210A1 CL 2016001210 A1 CL2016001210 A1 CL 2016001210A1 CL 2016001210 A CL2016001210 A CL 2016001210A CL 2016001210 A CL2016001210 A CL 2016001210A CL 2016001210 A1 CL2016001210 A1 CL 2016001210A1
Authority
CL
Chile
Prior art keywords
bicalutamide
treatment
glycogenosis
analogs
activating compounds
Prior art date
Application number
CL2016001210A
Other languages
English (en)
Inventor
Obiols Berta Ponsati
Josep Farrera-Sinfreu
Borrel Leslie Matalonga
Mas Laura Gort
Martinez Roberto Pascual
Montiel Antonio Ferrer
Rubio Antonio Ribes
Original Assignee
Bcn Peptides Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50238086&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016001210(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bcn Peptides Sa filed Critical Bcn Peptides Sa
Publication of CL2016001210A1 publication Critical patent/CL2016001210A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/41—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
    • C07C331/16—Isothiocyanates
    • C07C331/28—Isothiocyanates having isothiocyanate groups bound to carbon atoms of six-membered aromatic rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7057—(Intracellular) signaling and trafficking pathways
    • G01N2800/7066—Metabolic pathways

Abstract

USO DEL COMPUESTO (S)-BICALUTAMIDA PARA EL TRATAMIENTO DE UN DESORDEN DE ACÚMULO LISOSOMAL O GLUCOGENOSIS Y COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE A DICHO COMPUESTO.
CL2016001210A 2013-12-23 2016-05-19 Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis. CL2016001210A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13382541 2013-12-23

Publications (1)

Publication Number Publication Date
CL2016001210A1 true CL2016001210A1 (es) 2016-12-16

Family

ID=50238086

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001210A CL2016001210A1 (es) 2013-12-23 2016-05-19 Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.

Country Status (21)

Country Link
US (1) US11571407B2 (es)
EP (1) EP3086784B9 (es)
JP (1) JP6546923B2 (es)
KR (1) KR102128145B1 (es)
CN (1) CN105828811B (es)
AU (1) AU2014372690B2 (es)
CA (1) CA2934772C (es)
CL (1) CL2016001210A1 (es)
DK (1) DK3086784T3 (es)
ES (1) ES2732308T3 (es)
HU (1) HUE043959T2 (es)
IL (1) IL245789B (es)
LT (1) LT3086784T (es)
MX (1) MX2016008283A (es)
MY (1) MY182903A (es)
NZ (1) NZ720499A (es)
PH (1) PH12016501168A1 (es)
PL (1) PL3086784T3 (es)
PT (1) PT3086784T (es)
RU (1) RU2685269C2 (es)
WO (1) WO2015097088A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
WO2017011318A1 (en) * 2015-07-10 2017-01-19 University Of Miami Methods for treating mucopolysaccharidosis
US10702571B2 (en) 2015-12-03 2020-07-07 The University Of North Carolina At Pembroke Materials for cathepsin B enhancement and methods of use
CA3010205A1 (en) 2015-12-30 2017-07-06 Amicus Therapeutics, Inc. Augmented acid alpha-glucosidase for the treatment of pompe disease
AU2017252563B2 (en) * 2016-04-21 2022-07-21 Baylor College Of Medicine Compositions and methods for the treatment of lysosomal storage disorders and disorders characterized by lysosomal dysfunction
WO2019210301A1 (en) * 2018-04-27 2019-10-31 The Medical College Of Wisconsin, Inc. Use of lentivector-transduced t-rapa cells for amelioration of lysosomal storage disorders
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
CN112807302A (zh) * 2021-02-05 2021-05-18 重庆西南果品营养研究院 橘皮素在制备控制人体血尿酸水平的药物或食品中的新用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE468159B (sv) 1991-03-25 1992-11-16 Alfa Laval Thermal Ab Foerfarande foer att belaegga vaermeoeverfoeringsplattor i en plattvaermevaexlare med ett skikt av ytskyddande material
US6071957A (en) * 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
US6160011A (en) * 1997-05-30 2000-12-12 The University Of Tennessee Research Corporation Non-steroidal agonist compounds and their use in male hormone therapy
AU7723198A (en) * 1997-06-04 1998-12-21 University Of Tennessee Research Corporation, The Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
US7026500B2 (en) * 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
WO2003074473A2 (en) * 2002-02-28 2003-09-12 University Of Tennessee Research Foundation Irreversible selective androgen receptor modulators and methods of use thereof
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
US20110237664A1 (en) 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
US8999389B2 (en) * 2006-03-14 2015-04-07 Lidds Ab Bioresorbable controlled-release composition
PT2533050E (pt) * 2006-05-16 2014-05-26 Amicus Therapeutics Inc Opções de tratamento para a doença de fabry
WO2008008433A2 (en) * 2006-07-12 2008-01-17 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
US20110237538A1 (en) 2008-08-06 2011-09-29 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
CA2752373C (en) * 2009-02-20 2017-10-10 To-Bbb Holding B.V. Glutathione-based drug delivery system
EP2486061A4 (en) * 2009-10-06 2013-08-28 Angiochem Inc COMPOSITIONS AND METHODS FOR THE TRANSPORT OF THERAPEUTICS
AU2011223706A1 (en) 2010-03-05 2012-09-20 Baylor Research Institute Involvement of androgen/androgen receptor pathway in Fabry disease
US9155784B2 (en) * 2011-06-20 2015-10-13 Icahn School Of Medicine At Mount Sinai Anti-TNF-α therapy for the mucopolysaccharidoses and other lysosomal disorders
US9393221B2 (en) 2011-07-20 2016-07-19 The General Hospital Corporation Methods and compounds for reducing intracellular lipid storage

Also Published As

Publication number Publication date
US11571407B2 (en) 2023-02-07
EP3086784B1 (en) 2019-03-27
ES2732308T3 (es) 2019-11-21
JP2017503781A (ja) 2017-02-02
CA2934772C (en) 2021-04-27
CN105828811B (zh) 2022-04-08
HUE043959T2 (hu) 2019-09-30
IL245789B (en) 2020-01-30
CN105828811A (zh) 2016-08-03
DK3086784T3 (da) 2019-06-17
CA2934772A1 (en) 2015-07-02
LT3086784T (lt) 2019-06-25
PL3086784T3 (pl) 2019-09-30
EP3086784B9 (en) 2019-10-16
KR102128145B1 (ko) 2020-06-30
EP3086784A1 (en) 2016-11-02
PH12016501168B1 (en) 2016-07-18
MY182903A (en) 2021-02-05
JP6546923B2 (ja) 2019-07-17
IL245789A0 (en) 2016-07-31
RU2016125883A3 (es) 2018-07-31
PH12016501168A1 (en) 2016-07-18
RU2685269C2 (ru) 2019-04-17
KR20160095174A (ko) 2016-08-10
RU2016125883A (ru) 2018-01-30
MX2016008283A (es) 2016-09-08
PT3086784T (pt) 2019-06-27
NZ720499A (en) 2020-04-24
US20160317489A1 (en) 2016-11-03
AU2014372690B2 (en) 2019-10-03
WO2015097088A1 (en) 2015-07-02
AU2014372690A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
CL2017003404A1 (es) Compuestos antibacterianos
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2016002772A1 (es) Composiciones de insulina de rápida acción
AR102712A1 (es) Agonistas parciales del receptor de insulina
CL2015003314A1 (es) Inhibidores de acc y usos de los mismos
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2013002898A1 (es) Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer.
UY35500A (es) Indazoles sustituidos con heteroarilo
DK3229810T3 (da) Phospholipid-ether-analoger som kræftrammende lægemiddelvehikler
CL2014002257A1 (es) Compuestos derivados de 6-alquinilo piridinas, como mimeticos smac; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o prevencion del cancer.
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
CL2016001349A1 (es) Uso de derivados de bencimidazol-prolina
CL2015000976A1 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados.
CL2014003429A1 (es) Compuestos especificos derivados de indanosulfamida; composicion farmaceutica que los comprende, utiles en el tratamiento e la epilepsia.
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
CL2016000038A1 (es) Piraxolo-piridinaminas sustituidas
CL2015003713A1 (es) Composición herbicida que tiene mejorada seguridad en plantas
DOP2017000058A (es) Derivados de tetrahidroquinolina como inhibidores del bromodominio
UY36373A (es) Compuestos para usarse en el tratamiento antihelmíntico
DOP2015000298A (es) Compuestos nuevos para el tratamiento del cáncer
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
ES2651188T8 (es) Composición líquida fotopolimerizable